Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CNR2 | P34972 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644275 | 0.93 | EPHX2 (0.65) | CNR1SLC6A5 | |
| SCHEMBL7644265 | 0.93 | EPHX2 (0.65) | CNR1SLC6A5 | |
| SCHEMBL15007554 | 0.85 | CNR1 (0.94) | CNR1MEN1KMT2AMAPTSLC6A5 | |
| SCHEMBL6543426 | 0.85 | CNR1 (0.71) | CNR1MEN1KMT2AMAPTSLC6A5 | |
| SCHEMBL8704897 | 0.85 | CNR1 (0.82) | CNR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28504986 | 0.85 | CNR1 (0.71) | CNR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14864051 | 0.85 | CNR1 (0.82) | CNR1MEN1KMT2AMAPTSLC6A5 | |
| SCHEMBL1308066 | 0.85 | CNR1 (0.71) | CNR1MEN1KMT2AMAPTSLC6A5 | |
| SCHEMBL13990679 | 0.84 | CASP2 (0.63) | MEN1KMT2AFAAH | |
| SCHEMBL9964253 | 0.84 | CNR1 (0.85) | CNR1MEN1KMT2AMAPTSLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977180-A | Anandamide analog compositions and method of treating intraocular hypertension using same | PATE DAVID W (NL) | 1999-11-02 | — | — | US | claimed |
| EP-0777415-A4 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | PATE DAVID W (NL) | 1999-06-16 | — | — | EP | claimed |
| EP-0777415-A1 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | Pate, David W. (NL) | 1997-06-11 | — | — | EP | claimed |
| US-5631297-A | MIXTURES WITH CYCLODEXTRIN | PATE DAVID W (NL) | 1997-05-20 | — | — | US | claimed |
| WO-1996001558-A1 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | PATE DAVID W (NL) | 1996-01-25 | — | — | WO | claimed |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| US-6974568-B2 | Treatment for cough | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-13 | — | — | US | disclosed |
| WO-2002047691-A9 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002047691-A1 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2002-06-20 | — | — | WO | disclosed |
| US-20020077322-A1 | Protection of neurons against glutamate-induced damage in glaucoma and other conditions | AYOUB GEORGE S (US) | 2002-06-20 | — | — | US | disclosed |
| US-5977180-A | Anandamide analog compositions and method of treating intraocular hypertension using same | PATE DAVID W (NL) | 1999-11-02 | — | — | US | disclosed |
| EP-0777415-A4 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | PATE DAVID W (NL) | 1999-06-16 | — | — | EP | disclosed |
| EP-0777415-A1 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | Pate, David W. (NL) | 1997-06-11 | — | — | EP | disclosed |
| US-5631297-A | MIXTURES WITH CYCLODEXTRIN | PATE DAVID W (NL) | 1997-05-20 | — | — | US | disclosed |
| WO-1996001558-A1 | ANANDAMIDE ANALOGUE COMPOSITIONS AND METHOD OF TREATING INTRAOCULAR HYPERTENTION USING SAME | PATE DAVID W (NL) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | CNR1 4/4885MEN1 4878/4885KMT2A 2333/4885 |
| US-20090082435-A1 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders | MGLL, PNLIP, LIPC | CNR1 273/4885MEN1 4743/4885KMT2A 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.